Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737388 | 0.88 | — | — | |
| SCHEMBL23995266 | 0.85 | — | — | |
| SCHEMBL23514721 | 0.83 | CYP2D6 (0.34) | — | |
| SCHEMBL19766492 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL24125960 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL17173253 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL23635321 | 0.73 | — | — | |
| SCHEMBL22404379 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL22510703 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL12030637 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| US-9593095-B2 | Methods for the treatment of bacterial infections | DUKE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593095-B2 | Methods for the treatment of bacterial infections | DUKE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20140371194-A1 | METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | THE UNIVERSITY OF KANSAS | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | SMN1; SMN2 2217/4885 |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | SMN1; SMN2 4077/4885 |
| US-20170001983-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | SMN1; SMN2 859/4885 |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | SMN1; SMN2 4077/4885 |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | SMN1; SMN2 4077/4885 |
| US-20140371194-A1 | METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CRYAB, HSP90B1, SERPINB1 | SMN1; SMN2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.